drugset / Trial / NCT04822363
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
Phase 0
Completed
112 enrolled
Beth Israel Deaconess Medical Center
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy of the two tests. The secondary goals will be to evaluate the pharmacodynamic parameters of the antiplatelet agents across the two testing modalities and refine the cutoffs used for the novel assay.
Timeline
- Start
- 2021-08-20
- Primary completion
- 2025-05-09
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Aspirin | Small molecule | 325 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | — |
Indications
No indication recorded.